Gastroenterologist Reviewed Every Major IBS Treatment at 12 Months. The Results Looked Nothing Like the 6-Week Data.

"Most IBS treatments look good at 6 weeks," says Prof. Magnus Simren, professor of gastroenterology at the University of Gothenburg. "The question I ask is: what happens at 12 months?"

It's a question most patients never think to ask. And when you see the data, it becomes obvious why the answers are rarely volunteered.

Prof. Simren's research group has tracked IBS patients through twelve months and beyond across a range of treatment types. The patterns are consistent. And they look nothing like the short-term data that fills most clinical guidelines.

Why treatments always seem to work at first

There is a structural bias built into how IBS trials get designed.

The first six to eight weeks of any new treatment tend to show the highest effect. Part of this is genuine treatment response. Part of it is placebo effect, which runs unusually high in IBS, around 40 percent in well-designed trials. Part of it is the novelty of any new therapeutic engagement.

Regulatory approval requires demonstrating efficacy over a short, defined window. Most trials run for four to twelve weeks. This means most of the evidence guiding prescribing decisions is built on the period when treatments look their best.

"The six-week data is not the wrong data," Prof. Simren says. "It just doesn't answer the question patients actually need answered."

What happens to each treatment at 12 months

Here is what the long-term evidence actually shows:

• ❌ Low-FODMAP. Short-term response of 50 to 70 percent. At 12 months, adherence has dropped significantly and microbiome diversity has declined in patients who stayed on the diet. Manages the condition. Doesn't resolve it.
• ❌ Antispasmodics. Genuine acute relief. Benefit for about one in five patients beyond placebo per the Cochrane review. At 12 months: no mechanism modification, ongoing medication required for any continued benefit.
• ❌ Probiotics. Short-term benefit for bloating in some patients. The Gastroenterology systematic review rated certainty of evidence as low to very low. Twelve-month data is sparse.
• ❌ Low-dose antidepressants. The strongest pharmacological mechanism, acting on the gut-brain pathway. The ATLANTIS trial found real benefit. But effects are entirely medication-dependent: stop the drug, symptoms return. 38 percent of participants discontinued due to side effects.

The pattern is the same across all of them. Symptom management while the intervention is active. No lasting change in the gut's underlying sensitivity.

The one treatment that holds at 12 months

Gut-directed hypnotherapy shows a completely different pattern.

Short-term response rates of 70 percent are established across multiple replications of the Manchester Protocol trials. The finding that separates this treatment from every alternative is what happens after treatment ends.

A long-term follow-up study found that over 80 percent of initial responders were still showing clinically significant improvement at five years. No ongoing compliance required.

"This is the key distinction," Prof. Simren explains. "Symptom management versus mechanism modification. Most of what we prescribe manages symptoms. A small number of treatments change the mechanism. The long-term outcomes look completely different."

The mechanism accounts for the durability. Functional MRI studies show gut-directed hypnotherapy produces measurable changes in brain regions responsible for visceral pain processing. When the treatment works, it changes how the brain interprets signals from the gut. The threshold shifts. The symptoms don't come back because the neural pattern that was generating them has been modified.

A question worth asking about any IBS treatment you are considering

Prof. Simren's research group uses a simple framework for evaluating IBS treatments at a meaningful time horizon.

The relevant questions are not whether symptoms improved in the first month. They are:

• Is the improvement still present at six months?
• Does the benefit persist after the treatment is stopped, or only while you are actively compliant?
• Is the gut's underlying sensitivity changing, or is the treatment just reducing inputs to a gut that is still hypersensitive?

Dietary restriction, antispasmodics, and probiotics score well on short-term metrics and poorly on long-term ones. Gut-directed hypnotherapy scores well at both, and specifically at the time point that matters most.

For readers who want to know whether gut-directed hypnotherapy could help their IBS symptoms, ibsrelief.app/quiz offers a free 2-minute quiz. It covers the criteria discussed in this article: symptom severity, stress responsiveness, and treatment history. It is not a diagnostic tool, but it can help you see whether gut-directed hypnotherapy is worth exploring for your situation.